Alto Neuroscience Inc (ANRO)
18.99
-1.71%
Alto Neuroscience Inc (ANRO) is currently trading at $18.99. This represents a loss of 1.71% from the previous session. With a market capitalization of $0.59B, ANRO is a key component of the Biotechnology sector. Investors looking to trade ANRO should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade ANRO commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Alto Neuroscience Inc (ANRO) shows a bearish trend. Analysts are watching the 19.85 level closely.
Fundamentals
Mkt Cap0.59B
P/E Ratio0.0000
Volume109,544
60-Day Technical Chart
Advanced Charting
Need more indicators for ANRO? Use the world's #1 platform.
Open ANRO on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $19
| Metric |
ANRO -1.71% |
SOFI +3.38% |
HPQ +0.05% |
KVUE -1.26% |
|---|---|---|---|---|
| Price | $18.99 | $19.29 | $18.21 | $18.77 |
| Mkt Cap | $0.59B | $24.60B | $16.72B | $35.98B |
| - | View → | View → | View → |
Latest Headlines
Biotech investors get two chances to meet Alto Neuroscience in March
Stock Titan • Feb 23, 2026
Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy
Yahoo Finance • Oct 23, 2025
ANRO STOCK NEWS: Alto Neuroscience, Inc. Investors are Reminded of the Pending Lead Plaintiff Deadline; Contact Robbins LLP for Information on Leading the Class Action
PR Newswire • Sep 2, 2025
ANRO: BTIG Analyst Maintains 'Buy' Rating, Raises Price Target t
GuruFocus • Feb 17, 2026
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Business Wire • Feb 13, 2026
● Gemini Agentic AI Analyst Insight for ANRO
Market Education
- The Animal Trading Playbook Sep 8, 2025
- Large Cap at Lowest Price Apr 9, 2024
- How to Protect and Grow Wealth as Interest Rates Fall Sep 27, 2025
External Research